SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 235 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.09 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $613,953 | 0.0% | 16,946 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $613,953 | +8.8% | 16,946 | +7.1% | 0.00% | 0.0% |
| Q4 2022 | $564,405 | +6.1% | 15,823 | +0.5% | 0.00% | 0.0% |
| Q3 2022 | $532,000 | +16.7% | 15,744 | -0.4% | 0.00% | 0.0% |
| Q2 2022 | $456,000 | -95.1% | 15,807 | -94.6% | 0.00% | -93.5% |
| Q1 2022 | $9,379,000 | -42.2% | 290,217 | -47.9% | 0.05% | -40.3% |
| Q4 2021 | $16,239,000 | +8.0% | 556,929 | -1.2% | 0.08% | -1.3% |
| Q3 2021 | $15,032,000 | -14.0% | 563,675 | -0.7% | 0.08% | -13.3% |
| Q2 2021 | $17,485,000 | +17.3% | 567,929 | -0.3% | 0.09% | +12.5% |
| Q1 2021 | $14,908,000 | +20.5% | 569,461 | +15.8% | 0.08% | +17.6% |
| Q4 2020 | $12,371,000 | +11.9% | 491,734 | -7.3% | 0.07% | +3.0% |
| Q3 2020 | $11,054,000 | -23.9% | 530,460 | -13.3% | 0.07% | -25.8% |
| Q2 2020 | $14,533,000 | -21.7% | 611,964 | -21.8% | 0.09% | +4.7% |
| Q1 2020 | $18,549,000 | 0.0% | 782,079 | 0.0% | 0.08% | 0.0% |
| Q4 2019 | $18,549,000 | -23.7% | 782,079 | -11.6% | 0.08% | -23.4% |
| Q3 2019 | $24,311,000 | -29.9% | 884,714 | -15.6% | 0.11% | -27.0% |
| Q2 2019 | $34,667,000 | -23.0% | 1,047,709 | -18.5% | 0.15% | -25.5% |
| Q1 2019 | $45,028,000 | +12.5% | 1,285,082 | +6.7% | 0.20% | +4.6% |
| Q4 2018 | $40,018,000 | -20.0% | 1,204,665 | +21.3% | 0.20% | -2.5% |
| Q3 2018 | $50,020,000 | +28.0% | 993,483 | +52.2% | 0.20% | +15.6% |
| Q2 2018 | $39,071,000 | +55.0% | 652,806 | +3.2% | 0.17% | +64.8% |
| Q1 2018 | $25,215,000 | 0.0% | 632,794 | 0.0% | 0.10% | 0.0% |
| Q4 2017 | $25,215,000 | -12.6% | 632,794 | -12.2% | 0.10% | -16.7% |
| Q3 2017 | $28,842,000 | -13.9% | 721,097 | -32.8% | 0.13% | -21.2% |
| Q2 2017 | $33,514,000 | 0.0% | 1,073,335 | 0.0% | 0.16% | 0.0% |
| Q1 2017 | $33,514,000 | +14.7% | 1,073,335 | -7.2% | 0.16% | +0.6% |
| Q4 2016 | $29,210,000 | -24.3% | 1,156,872 | -25.8% | 0.16% | -26.7% |
| Q3 2016 | $38,568,000 | +6.5% | 1,559,612 | -12.3% | 0.22% | -1.4% |
| Q2 2016 | $36,224,000 | +29.1% | 1,778,395 | -3.4% | 0.22% | +20.9% |
| Q1 2016 | $28,062,000 | +10.2% | 1,840,280 | -2.9% | 0.18% | +4.6% |
| Q4 2015 | $25,476,000 | +52.2% | 1,895,663 | +58.8% | 0.17% | +41.5% |
| Q3 2015 | $16,744,000 | +3381.1% | 1,193,567 | +4110.0% | 0.12% | +4000.0% |
| Q2 2015 | $481,000 | – | 28,351 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ASHFORD CAPITAL MANAGEMENT INC | 921,962 | $33,402,683 | 5.00% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 423,500 | $15,326,465 | 4.28% |
| ARMISTICE CAPITAL, LLC | 4,350,000 | $157,600,500 | 2.27% |
| S&T BANK/PA | 223,775 | $8,107 | 1.46% |
| Aristotle Capital Boston, LLC | 1,155,149 | $41,851,071 | 1.29% |
| Tributary Capital Management, LLC | 353,671 | $12,813,500 | 1.19% |
| Bridge City Capital, LLC | 62,790 | $2,274,882 | 1.14% |
| RICE HALL JAMES & ASSOCIATES, LLC | 551,285 | $19,973,056 | 1.14% |
| Intrinsic Edge Capital Management LLC | 289,704 | $10,495,976 | 1.05% |
| Parkman Healthcare Partners LLC | 131,878 | $4,777,940 | 1.04% |